

Erratum to: Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents

Gais Kadra · Pascal Finetti · Yves Toiron ·
Patrice Viens · Daniel Birnbaum · Jean-Paul Borg ·
François Bertucci · Anthony Gonçalves

Published online: 14 February 2012
© Springer Science+Business Media, LLC. 2012

Erratum to: Breast Cancer Res Treat DOI 10.1007/s10549-011-1687-8

Author would like to amend the following corrections in the below Tables 3 and 4 which has been published unnoticed in the original version. Where, the article included an

unfortunate inversion between “Neg” and “Pos” rows for “ER”, “PR”, “Ki67” and “P53” in Tables 3 and 4. In Table 4, there was also an error in the percentages of grade 1 and 2 tumors with predicted taxane-sensitive and ixabepilone-resistant phenotype. The correct values are given in the tables presented below.

The online version of the original article can be found under doi:
[10.1007/s10549-011-1687-8](https://doi.org/10.1007/s10549-011-1687-8).

G. Kadra · Y. Toiron · J.-P. Borg · A. Gonçalves
Département de Pharmacologie Moléculaire and U891 INSERM,
Centre de Recherche en Cancérologie de Marseille, Institut
Paoli-Calmettes, Marseille, France

P. Finetti · D. Birnbaum · F. Bertucci
Département d’Oncologie Moléculaire and U891 INSERM,
Centre de Recherche en Cancérologie de Marseille, Institut
Paoli-Calmettes, Marseille, France

P. Viens · F. Bertucci · A. Gonçalves (✉)
Département d’Oncologie Médicale and U891 INSERM, Centre
de Recherche en Cancérologie de Marseille, Institut Paoli-
Calmettes, 232 Bd. Ste-Marguerite, 13009 Marseille, France
e-mail: gonalvesa@marseille.fnclcc.fr

P. Viens · J.-P. Borg · F. Bertucci · A. Gonçalves
Université de la Méditerranée, Marseille, France

Table 3 Clinical, pathological and molecular characteristics of 266 early breast cancer patients, according to their predicted sensitivity to taxanes and ixabepilone

	<i>N</i>	Taxane-resistant <i>N</i> = 147	Taxane-sensitive <i>N</i> = 119	<i>P</i> -value*	Ixabepilone-resistant <i>N</i> = 137	Ixabepilone-sensitive <i>N</i> = 129	<i>P</i> -value*
Age (years)	266						
≤50		49 (33%)	53 (45%)	0.08	45 (33%)	57 (44%)	0.059
>50		98 (67%)	66 (55%)		92 (67%)	72 (56%)	
ER	264						
Neg		23 (16%)	91 (76%)	4.71E−24	27 (20%)	87 (67%)	3.84E−15
Pos		122 (84%)	28 (24%)		108 (80%)	42 (33%)	
PR	264						
Neg		35 (24%)	93 (78%)	6.48E−19	39 (29%)	89 (69%)	8.52E−11
Pos		110 (76%)	26 (22%)		96 (71%)	40 (31%)	
pT	245						
pT1		45 (33%)	35 (32%)	0.89	36 (29%)	44 (36%)	0.28
pT2-T3		91 (67%)	74 (68%)		88 (71%)	77 (64%)	
Grade	259						
1		33 (23%)	12 (10%)	2.00E−05	28 (21%)	17 (13%)	3.04E−03
2		61 (43%)	28 (24%)		54 (41%)	35 (28%)	
3		48 (34%)	77 (66%)		50 (38%)	75 (59%)	
Ki67	227						
Neg		55 (43%)	18 (18%)	5.44E−05	44 (38%)	29 (26%)	0.07
Pos		72 (57%)	82 (82%)		72 (62%)	82 (74%)	
P53	194						
Neg		84 (76%)	41 (49%)	8.38E−05	75 (72%)	50 (56%)	2.38E−02
Pos		26 (24%)	43 (51%)		29 (28%)	40 (44%)	
Molecular subtype	266						
Basal		3 (2%)	72 (61%)	1.00E−05	11 (8%)	64 (50%)	1.00E−05
HER2		12 (8%)	12 (10%)		11 (8%)	13 (10%)	
Luminal A		78 (53%)	11 (9%)		65 (47%)	24 (19%)	
Luminal B		46 (31%)	3 (3%)		41 (30%)	8 (6%)	
Normal		8 (5%)	21 (18%)		9 (7%)	20 (16%)	
Ixabepilone-sensitivity	266						
Re		119 (81%)	18 (15%)	2.17E−28	–	–	
Se		28 (19%)	101 (85%)		–	–	

* Fisher's exact test

Table 4 Clinical, pathological and molecular characteristics of 46 early breast cancer patients, predicted to have differential sensitivity to taxanes and ixabepilone

	<i>N</i>	Ixabepilone-sensitive Taxane-resistant <i>N</i> = 28	Taxane-sensitive Ixabepilone-resistant <i>N</i> = 18	<i>P</i> -value*
Age (years)	46			
≤50		9 (32%)	5 (28%)	1
>50		19 (68%)	13 (72%)	
ER	46			
Neg		10 (36%)	14 (78%)	7.20E−3
Pos		18 (64%)	4 (22%)	
PR	46			
Neg		10 (36%)	14 (78%)	7.20E−3
Pos		18 (64%)	4 (22%)	
pT	42			
pT1		13 (48%)	4 (27%)	0.21
pT2-T3		14 (52%)	11 (73%)	
Grade	46			
1		8 (29%)	3 (17%)	0.14
2		10 (36%)	3 (17%)	
3		10 (36%)	12 (66%)	
Ki67	39			
Neg		14 (56%)	3 (21%)	0.049
Pos		11 (44%)	11 (79%)	
P53	34			
Neg		17 (85%)	8 (57%)	0.12
Pos		3 (15%)	6 (43%)	
Molecular subtype	46			
Basal		1 (4%)	9 (50%)	1.50E−04
HER2		5 (18%)	4 (22%)	
Luminal A		14 (50%)	1 (6%)	
Luminal B		6 (21%)	1 (6%)	
Normal		2 (7%)	3 (17%)	

* Fisher's exact test